Skip to main content

Table 1 Studies Comparing Outcomes in Advanced Malignancy Patients on Treatment with Anti-Programmed Cell Death Protein 1 (PD-1) and Anti-Programmed Death-Ligand 1 (PD-L1) Antibodies

From: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Study Disease Number of Patients Checkpoint Inhibitor(s) Used Survival Endpoints Between Patients With and Without IRAES Response Endpoints Between Patients With and Without IRAEs
Grangeon et al. [18] NSCLC 270 Anti-PD-1 and anti-PD-L1 OS (HR 0.29; 95% CI 0.18–0.46; p = .001), PFS (HR 0.42; 95% CI 0.32–0.57; p < .001) ORR (22.9% vs 5.7%, p < .0001), DCR (76% vs 58%, p < .001)
Ricciuti et al. [34] NSCLC 195 Nivolumab OS (HR 0.33; 95% CI 0.23–0.47; p < .001), PFS (HR 0.41; 95% CI 0.3–0.57; p < .001) ORR (43.5% vs 10%, p < .001), DCR (70.5% vs 18.1%, p < .0001)
Riudavets et al. [13] NSCLC, UCC and melanoma 178 Nivolumab, pembrolizumab and atezolizumab OS (37.3 vs 7.8 months, p < 0.0001), PFS (7.9 vs 2.6 months, p < 0.0001) Not provided
Sato et al.a [19] NSCLC 38 Nivolumab PFS (HR 0.1; 95% CI .02–.37; p < .001) ORR (63.6% vs 7.4%, p < .01)
Weber et al. [38] Melanoma 576 Nivolumab PFS (no significant differences between either group; HR or p value not provided) ORR (48.6% vs 17.8%, p < .001)
Indini et al. [37] Melanoma 173 Anti-PD-1 OS (HR 0.39; 95% CI 0.18–0.81; p = .007), PFS (HR 0.47; 95% CI 0.26–0.86; p = .016) ORR (HR 1.95; 95% CI 0.91–4.15; p < 0.082), DCR (HR 1.98; 95% CI 1.07–3.67; p < 0.029)
Elias et al. [17] RCC 90 Anti-PD-1 OS (HR 0.38; 95% CI 0.18–0.79; p = .01) and TTNT (HR 0.48; 95% CI 0.28–0.83; p = .008) Not provided
Verzoni et al. [39] RCC 389 Nivolumab OS (HR .57; 95% CI .35–.93; p = .02) Not provided
Maher et al. [20] UCC 1747 Atezolizumab or pembrolizumab OS (HR 0.53; 95% CI 0.43–0.66) Not provided
Morales-Berera et al. [40] UCC 52 Anti-PD-1 or anti-PD-L1 OS (21.91 vs 6.47 months, p = .004) DCR (79% vs 36.3%, p = .002)
Das et al. [41] GI 61 Anti-PD-1 monotherapy or in combination OS (32.4 vs 8.5 months, p = .0036), PFS (32.4 vs 4.8 months, p = .0001) Not provided
Masuda et al. [42] Gastric 65 Nivolumab OS (HR .17, p < .001), PFS (HR .11, p < .001) Not provided
Foster et al. [43] HNSCC 114 Anti PD-1 OS (12.5 vs 6.8 months, p = .0007), PFS (6.9 vs 2.1 months, p = .0004) ORR (30.6% vs 12.3%, p = .02)
  1. Abbreviations: NSCLC non-small cell lung cancer, UCC urothelial cell carcinoma, RCC renal cell carcinoma, GI gastrointestinal, HNSCC head and neck squamous cell carcinoma, IRAEs immune related adverse events, OS overall survival, PFS progression-free survival, ORR overall response rate, DCR disease control rate, HR hazard ratio, CI confidence interval, TTNT time to next treatment, vs versus
  2. aProspective study